A rizatriptan, benzoate CEP of the European Pharmacopoeia monograph is often referred to as a rizatriptan, benzoate Certificate of Suitability (COS). The purpose of a rizatriptan, benzoate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of rizatriptan, benzoate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of rizatriptan, benzoate to their clients by showing that a rizatriptan, benzoate CEP has been issued for it. The manufacturer submits a rizatriptan, benzoate CEP (COS) as part of the market authorization procedure, and it takes on the role of a rizatriptan, benzoate CEP holder for the record. Additionally, the data presented in the rizatriptan, benzoate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the rizatriptan, benzoate DMF.
A rizatriptan, benzoate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. rizatriptan, benzoate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of rizatriptan, benzoate suppliers with CEP (COS) on PharmaCompass.